stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.41
0.51
+3.67%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) EBITDA
Biohaven Ltd.'s EBITDA for fiscal 2025 was −$735.5M, compared with −$877.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$515.1M. Over the past ten years it has ranged from −$877.3M (fiscal 2024) to −$9.7M (fiscal 2015); the current reading is higher than 18% of that period. Biohaven Ltd. ranks 578th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$735.5M | — |
| FY2024 | −$877.3M | — |
| FY2023 | −$429.1M | — |
| FY2022 | −$566.5M | — |
| FY2021 | −$217.5M | — |
| FY2020 | −$114.4M | — |
| FY2019 | −$478.5M | — |
| FY2018 | −$220.2M | — |
| FY2017 | −$107.6M | — |
| FY2016 | −$60.6M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$124.2M | — |
| Jun 2026 | −$122.6M | — |
| Mar 2026 | −$128.1M | — |
| Dec 2025 | −$140.2M | — |
| 39 more quarters | Free account |
Against its own ten years
Low −$877.3M
High −$9.7M
Ten-year median
−$220.2M
Current reading's percentile
18
EBITDA against peers
| Company | EBITDA |
|---|---|
| ADMA ADMA Biologics Inc compare | $232.8M |
| AUPH Aurinia Pharmaceuticals Inc compare | $163.4M |
| VCEL Vericel Corporation compare | $31.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$57.7M |
| IMNM Immunome, Inc. compare | −$268.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$326.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$416.8M |
| VERA Vera Therapeutics, Inc. compare | −$417.0M |
| BHVN Biohaven Ltd. | −$515.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item